Dr. Michael Bruner has more than 15 years of experience representing clients in pharmaceutical and chemical intellectual property matters, such as the development of global patent portfolios to protect their innovations. He guides clients from the early stages of patent portfolio development when leads are initially identified, continuing through the product development process as new filing opportunities arise.
A particular focus of his practice is to advise clients with respect to patent life-cycle strategies and regulatory extension opportunities as the portfolio matures and regulatory approval approaches. He also advises clients on due diligence matters, including those relating to clients’ investment in or acquisition of third parties, as well as licensing and collaboration opportunities.
A further aspect of Michael’s practice is providing clients with opinions relating to patentability, freedom-to-operate, noninfringement, and validity. Prior to attending law school, Michael performed postdoctoral research at the Centers for Disease Control and Prevention (CDC) in the areas of vaccine and infectious diseases.
- Fordham University (J.D. cum laude 2005; awarded 2005 Benjamin Finkel Prize for excellence in bankruptcy);
- Centers for Disease Control and Prevention, Atlanta (American Society for Microbiology Postdoctoral Research Fellowship in the areas of vaccine and infectious diseases, 1999-2001);
- University of Florida, Gainesville (Ph.D. 1999 under the guidance of Dr. Ben Horenstein);
- University of West Florida, Pensacola (B.S. in Chemistry 1994)
BAR ADMISSIONS :
- New York, and registered to practice before the United States Patent and Trademark Office
- Celgene establishes global patent portfolio for small molecule pharmaceuticals
- Signal Pharmaceuticals maintains patent portfolio for small molecule kinase inhibitors
- Georgia-Pacific faces Nat’l Gypsum parent in DJ action over wallboards
- Danske Markets and Handelsbanken Capital Markets act as placement agent in €59.3 million rights offering by Danish biopharmaceutical company
- Bioenvision develops patent portfolios for Clolar® and Modrenal®
- Esperion establishes patent portfolios for small molecule cholesterol-lowering drugs
Rate : $$$$